

DISCLOSURE STATEMENT

Title: Mean Reversion in Randomized Controlled Trials: Implications for Program Targeting and Heterogeneous Treatment Effects.

I have no disclosures to report.

I gratefully acknowledge the MIT Sloan Health Systems Initiative and the Jameel Poverty Action Lab, which funded research assistance and research management on this project.

The study was approved by the Geisinger Institutional Review Board, IRB# 2018-0297.
The study was registered with clinicaltrials.gov clinicaltrials.gov (NCT03718832) and American Economic Association, AEARCTR-0004098.

